1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,328 | 0,392 | 08:18 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 04.09. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 28.08. | IMMUNEONCO-B (01541): (1) RESIGNATION OF INDEPENDENT NON-EXECUTIVE DIRECTOR; AND (2) PROPOSED APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR | - | HKEx | ||
| IMMUNEONCO BIOPHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 27.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PHASE II CLINICAL TRIAL OF IMM2510 IN COMBINATION WITH IMM27M FOR FIRST-LINE TREATMENT ... | 1 | HKEx | ||
| 26.08. | IMMUNEONCO-B (01541): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 25.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN PAH TRIAL AND COMPLETION OF ENROLMENT FOR SAD AND MAD COHORTS FOR IMC-003 | - | HKEx | ||
| 23.08. | IMMUNEONCO-B IMM0306 Clinical Trial Application Approved by US FDA | 1 | AASTOCKS | ||
| 21.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - APPROVAL OF IND APPLICATION OF IMM0306 FOR PHASE IB/II CLINICAL TRIAL FOR THE TREATMENT OF SYSTEMIC LUPUS ... | 1 | HKEx | ||
| 14.08. | IMMUNEONCO-B (01541): DATE OF BOARD MEETING | 1 | HKEx | ||
| 07.08. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - ENTERING INTO THE CAPITAL INCREASE OF A SUBSIDIARY | 2 | HKEx | ||
| 31.07. | IMMUNEONCO-B (01541): SUPPLEMENTAL ANNOUNCEMENT - DEEMED DISPOSAL IN RELATION TO CAPITAL INCREASE OF A SUBSIDIARY | 2 | HKEx | ||
| 17.07. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 10.07. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSED IN THE PHASE II/III CLINICAL TRIAL OF IMM0306 FOR THE TREATMENT OF IGG4-RELATED DISEASE | 2 | HKEx | ||
| 06.07. | IMMUNEONCO-B (01541): (REVISED) NEXT DAY DISCLOSURE RETURNS | 2 | HKEx | ||
| 03.07. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 02.07. | IMMUNEONCO-B (01541): ANNOUNCEMENT PURSUANT TO RULES 14A.36, 14A.39 AND 14A.46 OF THE LISTING RULES | - | HKEx | ||
| 24.06. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 18.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - DEEMED DISPOSAL IN RELATION TO CAPITAL INCREASE OF A SUBSIDIARY | 2 | HKEx | ||
| 17.06. | IMMUNEONCO-B (01541): DISCLOSEABLE TRANSACTIONS - SUBSCRIPTION OF WEALTH MANAGEMENT PRODUCT | 1 | HKEx | ||
| 16.06. | IMMUNEONCO-B (01541): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 08.06. | IMMUNEONCO-B (01541): VOLUNTARY ANNOUNCEMENT - ON-MARKET SHARE REPURCHASE | 2 | HKEx |
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 72,00 | 0,00 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| ERASCA | 16,040 | +0,06 % | FDA Fast Track Puts Erasca's (ERAS) Pancreatic Bet Center Stage | ||
| RELAY THERAPEUTICS | 18,890 | 0,00 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen | ||
| HARMONY BIOSCIENCES | 41,100 | 0,00 % | Harmony Biosciences stellt auf Cantor-Konferenz erweiterte Wachstumsstrategie vor | ||
| ADMA BIOLOGICS | 9,390 | 0,00 % | Kehoe Law Firm, P.C.: ADMA Biologics (ADMA) Shareholder Alert: Kehoe Law Firm Investigates Potential Fiduciary Duty Breaches | Philadelphia, Pennsylvania--(Newsfile Corp. - August 5, 2026) - Kehoe Law Firm, P.C. is investigating whether certain officers and directors of ADMA Biologics, Inc. ("ADMA," "ADMA Biologics," or... ► Artikel lesen | |
| KINIKSA PHARMACEUTICALS | 76,48 | 0,00 % | Kiniksa Pharmaceuticals International, Plc: Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution | - ARCALYST (rilonacept) Q2 2026 net product revenue of $243.6 million, representing ~55% year-over-year growth -- ARCALYST 2026 expected net product revenue increased to $980 - $995 million -- KPL-387... ► Artikel lesen | |
| QIAGEN | 36,615 | -0,01 % | QIAGEN N.V. - 6-K, Report of foreign issuer | ||
| IMMUNOME | 24,970 | 0,00 % | Immunome: Varegacestat Cuts Progression Or Death Risk 84% As FDA Decision Targets April 2027 | ||
| TANGO THERAPEUTICS | 23,390 | +0,09 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 29,300 | 0,00 % | Mineralys auf Wells Fargo Konferenz: Markteinführung von Lorundrostat nimmt Gestalt an | ||
| DYNE THERAPEUTICS | 18,415 | -0,03 % | Aktien New York Ausblick: Dow schwächelt weiter - Nasdaq stabil erwartet | NEW YORK (dpa-AFX) - Die US-Börsen steuern nach dem verlängerten Wochenende am Dienstag auf eine durchwachsene Eröffnung zu. Auf die Stimmung drückten die weiter steigenden Ölpreise, die der Angst... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 10,580 | 0,00 % | Vir Biotechnology, Inc.: Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026 | - Oral presentation of complete Week 96 data from the Phase 2 SOLSTICE trial in chronic hepatitis delta selected for inclusion in "Best of EASL 2026" by EASL - Poster presentation of Week 48... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 111,42 | 0,00 % | Inhibrx Biosciences, Inc.: Inhibrx's INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study | First OX40 agonist to demonstrate clinical benefit in a randomized study
INBRX-106 plus pembrolizumab delivers a 48.3% cORR and 72.4% of patients remain progression... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,020 | +0,12 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| VERA THERAPEUTICS | 33,560 | -0,12 % | Vera Therapeutics: Erfolgreicher Start für Nierenmedikament TRUTAKNA |
IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell 0,00 % bei einem Aktienkurs von 0,338 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu IMMUNEONCO BIOPHARMACEUTICALS SHANGHAI INC finden Sie auf Wallstreet Online.